Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis

References

• Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–458.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
   PubMed Web of Science ®Google Scholar
• Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253:453–469.
   PubMed Web of Science ®Google Scholar
• Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:1437–1445.
   PubMed Web of Science ®Google Scholar
• Cheng X, Sun P, Hu QG, et al. Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses. J Cancer Res Clin Oncol. 2014;140:1159–1170.
   PubMed Web of Science ®Google Scholar
• Qi X, Liu L, Wang D, et al. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget. 2015;6:36838–36859.
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–853.
   PubMed Web of Science ®Google Scholar
• Sun JJ, Wang K, Zhang CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after r0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol. 2016;23:1344–1351.
   PubMed Web of Science ®Google Scholar
• Liu C, Sun L, Xu J, et al. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma. World J Surg Onc. 2016;14:100.
   PubMed Web of Science ®Google Scholar
• Bai T, Chen J, Xie ZB, et al. The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus. Onco Targets Ther. 2016;9:3841–3848.
   PubMed Web of Science ®Google Scholar
• Li F, Guo Z, Zhang Y, et al. Postoperative adjuvant arterial chemoembolization improves the survival of hepatitis B virus-related hepatocellular carcinoma: a retrospective control study. Ir J Med Sci. 2015;184:753–759.
   PubMed Web of Science ®Google Scholar
• Jiang JH, Guo Z, Lu HF, et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis. World J Gastroenterol. 2015;21:4627–4634.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [Internet]. The Cochrane Collaboration; 2011 [updated 2011 Mar; cited 2017 Feb 1]. Available from: http://www.cochrane-handbook.org
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–341.
   PubMed Web of Science ®Google Scholar
• Marcano Belisario JS, Tudor Car L, Reeves TJA, et al. Search strategies to identify observational studies in MEDLINE and EMBASE (Protocol). Cochrane Database Syst Rev. 2013. DOI:10.1002/14651858.MR000041
   Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Internet]. [cited 2017 Feb 1]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
   Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statist Med. 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Cheng SQWM, Chen H, Shen F, et al. Hepatocellular carcinoma with tumor thrombi in the portal vein. A comparison of therapeutic effects by different treatments. Zhonghua Zhong Liu Za Zhi. 2005;27:183–185.
   PubMedGoogle Scholar
• Xu F, Huang Y, Wu L, et al. Postoperative adjuvant transcatheter arterial chemoembolization for hepatocellular carcinoma: a prospective study. Acad J Second Mil Med Univ. 2012;33:390–394.
   Google Scholar
• Yu ZP, Xu ZK, Zhou WZ, et al. The effcacy of transarterial chemoembolization for hepatocellular carcinoma after curative resection. J Pract Med. 2009;25:1819–1821.
   Google Scholar
• Xiao Y, Liu T, Ruan T, et al. Value of transcatheter arterial chemoembolization with gemcitabine plus oxaliplatin in preventing postoperative recurrence of hepatocellular carcinoma in high-risk patients. World Chin J Digestol. 2012;20:238–242.
   Google Scholar
• Liu Y, Zhang X, Zhang J, et al. Transarterial chemoembolization as an adjuvant therapy in patients with hepatocellular carcinoma treated with hepatectomy. Chin J Radiol. 2010;44:847–851.
   Google Scholar
• Yan Q, Ni J, Zhang GL, et al. Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence. Chin Med J. 2013;126:855–859.
   PubMed Web of Science ®Google Scholar
• Xu F, Huang Y, Li Y, et al. Is postoperative adjuvant transchatheter arterial chemoembolization necessary for small hepatocellular carcinoma patients: a randomized controlled trial. Acad J Second Mil Med Univ. 2012;33:274–279.
   Google Scholar
• Xi T, Lai EC, Min AR, et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. Hepatogastroenterology. 2012;59:1198–1203.
   PubMed Web of Science ®Google Scholar
• Ren ZG, Lin ZY, Xia JL, et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. WJG. 2004;10:2791–2794.
   PubMed Web of Science ®Google Scholar
• Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009;198:313–318.
   PubMed Web of Science ®Google Scholar
• Li Q, Wang J, Sun Y, et al. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases. Dig Surg. 2006;23:235–240.
   PubMed Web of Science ®Google Scholar
• Li Q, Wang J, Sun Y, et al. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis–a randomized study. World J Surg. 2006;30:2004–2011. discussion 12–3.
   PubMed Web of Science ®Google Scholar
• Li K, Wen T, Li X, et al. The effect of postoperative TACE on prognosis of HCC with microscopic venous invasion. Hepatogastroenterology. 2012;59:1944–1946.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang Y, Zhang W, et al. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol. 1995;121:364–366.
   PubMed Web of Science ®Google Scholar
• Izumi R, Shimizu K, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology. 1994;20:295–301.
   PubMed Web of Science ®Google Scholar
• Mathurin P, Raynard B, Dharancy S, et al. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther. 2003;17:1247–1261.
   PubMed Web of Science ®Google Scholar
• Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. Hepatol Res. 2010;40:943–953.
   PubMed Web of Science ®Google Scholar
• Ueno S, Tanabe G, Yoshida A, et al. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer. 1999;86:248–254.
   PubMed Web of Science ®Google Scholar
• Takenaka K, Yoshida K, Nishizaki T, et al. Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg. 1995;169:400–404. discussion 5.
   PubMed Web of Science ®Google Scholar
• Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 1999;353:797–801.
   PubMed Web of Science ®Google Scholar
• Shimoda M, Tago K, Shiraki T, et al. Risk Factors for Early Recurrence of Single Lesion Hepatocellular Carcinoma After Curative Resection. World J Surg. 2016;40:2466–2471.
   PubMed Web of Science ®Google Scholar
• Chun JM, Kwon HJ, Sohn J, et al. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol. 2011;103:148–151.
   PubMed Web of Science ®Google Scholar
• Bhargava P, Gammon DC, Kim D, et al. Chemoembolization (CE) with carboplatin and doxorubicin for hepatocellular cancer (HCC): introduction of a novel combination and preliminary results. J Clin Oncol. 2004;22:4275.
   Web of Science ®Google Scholar
• Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.
   PubMed Web of Science ®Google Scholar
• Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs. 2004;15:427–437.
   PubMed Web of Science ®Google Scholar
• Sahara S, Kawai N, Sato M, et al. Prospective Evaluation of Transcatheter Arterial Chemoembolization (TACE) with Multiple Anti-Cancer Drugs (Epirubicin, Cisplatin, Mitomycin C, 5-Fluorouracil) Compared with TACE with Epirubicin for Treatment of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2012;35:1363–1371.
   PubMed Web of Science ®Google Scholar
• Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6–25.
   PubMed Web of Science ®Google Scholar